肝动脉灌注化疗在晚期肝癌中的临床应用研究进展  

Clinical application of hepatic artery infusion chemotherapy in advanced liver cancer

作　　者：张永镇 赵梦鹏 王文明[1] 韩新强[1] ZHANG Yongzhen;ZHAO Mengpeng;WANG Wenming;HAN Xinqiang(Department of Interventional Medicine and Vascular Surgery,Binzhou Medical University Hospital,Shandong Binzhou 256603,China)

机构地区：[1]滨州医学院附属医院介入血管外科,山东滨州256603

出　　处：《临床普外科电子杂志》2022年第4期34-40,共7页Journal of General Surgery for Clinicians(Electronic Version)

摘　　要：原发性肝细胞癌(hepatocellular carcinoma,HCC)是世界六大常见恶性肿瘤之一,早期诊断并及时手术切除能使患者最大获益。然而,基于肝脏独特的病理生理学特性,大多数患者在初诊时已为肿瘤晚期,失去手术切除机会;经肝动脉化疗栓塞术(transcatheter arterial chemoembolization,TACE)是其经典治疗手段,但对于伴门静脉癌栓(portal vein tumor thrombus,PVTT)的HCC患者是TACE治疗的相对禁忌;肝动脉灌注化疗(hepatic arterial infusion chemotherapy,HAIC)利用肝脏首过效应特点,直接向肿瘤供血动脉持续高浓度灌注化疗药物,近年来在中晚期HCC中取得令人瞩目的成绩,然而目前并未对HAIC形成统一的诊疗标准及规范,本文就HAIC在晚期HCC的临床应用做一综述。.Hepatocellular carcinoma(HCC)is one of the six most common malignant tumours globally.Early diagnosis and timely surgical resection can maximise the benefits for patients However,based on the unique pathophysiological characteristics of the liver,most patients have been in the advanced stage of the tumour at the initial diagnosis and lost the opportunity of surgical resection;transcatheter arterial chemoembolisation(TACE)is its definitive treatment,but HCC patients with portal vein tumor thrombus(PVTT)are relatively contraindicated to.TACE treatment Hepatic artery infusion chemotherapy(HAIC)using the characteristics of liverfirst-pass effect,continuous high-concentration infusion of chemotherapeutic drugs directly into tumour blood supply arteries has.made remarkable achievements in middle and advanced HCC in recent years However,there is no unified diagnosis.and treatment standard and specification for HAIC This paper reviews the clinical application of HAIC in advanced HCC.

关 键 词：肝动脉灌注化疗 化疗栓塞术 降期转化治疗 门静脉癌栓 

分 类 号：R73[医药卫生—肿瘤]